Entries |
Document | Title | Date |
20080227785 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE - This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. | 09-18-2008 |
20080249097 | PRODRUGS OF HETEROARYL COMPOUNDS - The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents. | 10-09-2008 |
20080255126 | Inhibitors of post-proline cleaving proteases - Novel compounds that are inhibitors of one or most post-proline cleaving proteases, e.g. dipeptidyl peptidase IV, according to general formula (1). R | 10-16-2008 |
20080255127 | Pesticide Formulations with a Crystallization Risk, and a Method for Their Preparation - Pesticide formulations with a crystallization risk are provided. Also provided are methods of making and using such formulations. | 10-16-2008 |
20080269224 | Substituted Triazines as Prion Protein Ligands and Their Use to Detect or Remove Prions - Compounds of formula (I) wherein R | 10-30-2008 |
20080269225 | Prokineticin 1 receptor antagonists - The present invention relates to certain novel compounds of Formula (I): | 10-30-2008 |
20080275049 | Methods and Compositions for Upregulation of GATA Activity - A novel method of identifying compounds capable of upregulating GATA activity is disclosed. The method includes providing a sample of cells that express GATA, providing a sample of a candidate compound, contacting the cell sample and the compound sample, and measuring a quantitative indicator of GATA activity within the cell sample after the contacting step. GATA inducers identified by the method and uses therefore to upregulate GATA activity in subjects and to prevent or treat atherosclerosis or diabetes in subjects are also described. | 11-06-2008 |
20080287445 | Prokineticin 2 receptor antagonists - The present invention relates to certain novel compounds of Formula (I): | 11-20-2008 |
20090030001 | THERAPEUTIC AGENT FOR CORNEAL DISEASE - A therapeutic agent for a corneal disease comprising irsogladine or a salt thereof as an active ingredient. The purpose is to find a substance capable of effectively treating/ameliorating a corneal disease which has been increased in the number of cases thereof in recent years and to provide a therapeutic agent for a corneal disease comprising the substance as an active ingredient. | 01-29-2009 |
20090082355 | Method of Combating Root Weevils - A method of combating root weevils comprising contacting the root weevils or their food supply, habitat, breeding grounds or their locus with a pesticidally effective amount of a compound of the formula (I) wherein W is Cl or CF | 03-26-2009 |
20090093485 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases - Compounds of formula (I) or a pharmaceutically acceptable salt thereof; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal). | 04-09-2009 |
20090093486 | INSECTICIDAL SUBSTITUTED AZINYL DERIVATIVES - N-Azinyl-N′-aryl ureas and thioureas derivatives are effective at controlling insects. | 04-09-2009 |
20090093487 | Compositions for topical application having androgenic actions - A composition comprising at least one physiologically tolerated film-forming agent, at least one physiologically tolerated solvent, at least one plasticizer and a compound of the formula I | 04-09-2009 |
20090143388 | TREATMENT OF BRAIN DISORDERS - Striatal neurodegenerative disorders, e.g. Parkinson's disease, are treated by administration of an effective dose of an antioxidant compound of formula I, formula II or a pharmaceutically acceptable salt thereof, in a regimen that decreases the adverse effects of the disorder. Such adverse effects can motor deficits, which include catalepsy or akinesia. Also provided are kits and systems for practicing the subject methods, as well as methods of use of agents identified in the screening method of the invention. | 06-04-2009 |
20090163505 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS - The present invention relates to certain novel compounds of Formula (I): | 06-25-2009 |
20090192164 | Treating agent of inflammatory bowel disease - The invention discloses treating agents of inflammatory bowel disease, which contain p38MAPkinase inhibitor having properties of antedrug as the active ingredient. | 07-30-2009 |
20090192165 | ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO - Disclosed are antimicrobial compositions for treating poultry and meat to substantially eliminate bacteria and microorganism harmful to human. The compositions include various combinations of an aliphatic heteroaryl salt, an aliphatic benzylalkyl ammonium salt, a dialiphatic dialkyl ammonium salt, a tetraalkyl ammonium salt and/or trichloromelamine. | 07-30-2009 |
20090233933 | Prostaglandin Transporter Inhibitors - Provided are methods of inhibiting prostaglandin transporter (PGT) activity in mammals. Also provided are methods of determining whether a test compound is an inhibitor of a prostaglandin transporter. Additionally provided are compounds that inhibit prostaglandin transporter activity, and pharmaceutical compositions of those compounds. Methods of inhibiting COX-2 in a mammal are also provided. Additionally, methods of treating pain or inflammation in a mammal are provided. | 09-17-2009 |
20090258878 | TRIAZINE DERIVATIVE COMPOUND AND COMPOSITION FOR TREATING CANCER CONTAINING THEM - The present invention relates to a Triazine derivative compound, pharmaceutically acceptable salt thereof and a pharmaceutical composition containing them. Compound or composition of the present invention is useful for cancer treatment, and especially has superior effect in breast cancer treatment. | 10-15-2009 |
20090270397 | Methods and compositions for the treatment of cancers, such as melanomas and gliomas - A method of potentiating the efficacy of an antineoplastic agent such as temozolomide, comprises the administration of an antifolate agent as defined herein. Also disclosed are compositions, including pharmaceutical compositions, comprising the antineoplastic agent and an antifolate agent, and the use of such compounds and compositions thereof to treat a variety of cancers, such as melanoma. Unit dosage forms and kits are also contemplated and disclosed. | 10-29-2009 |
20090275584 | BIOCIDAL COMBINATIONS COMPRISING IMAZALIL - The present invention relates to combinations of imazalil, or a salt thereof, and a biocidal compound which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of imazalil, or a salt thereof, together with one or more biocidal compounds selected from tolylfluanid, dichlofluanid, OIT, DCOIT, terbutryn, chlorothalonil, hexamin and 1,2-benzisothiazolone in respective proportions to provide a synergistic biocidal effect. Compositions comprising these combinations are useful for the protection of any living or non-living material, such as crops, plants, fruits, seeds, objects made of wood, thatch or the like, engineering material, biodegradable material and textiles against deterioration due to the action of microorganisms such as bacteria, fungi, yeasts, algae, viruses, and the like. | 11-05-2009 |
20090286794 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound - The present invention relates to preventives or remedies for Alzheimer's disease, or to amyloid protein fibril-formation inhibitors, which include as an active ingredient a compound of general formula (I) below or a pharmacologically permitted salt thereof; and also to nitrogen-containing heteroaryl derivatives having specific substituents, or pharmacologically permitted salts thereof, which are valuable as preventives or remedies for Alzheimer's disease, or as amyloid protein fibril-formation inhibitors: | 11-19-2009 |
20090306080 | VETERINARY FORMULATION - The present invention relates to a liquid veterinary formulation comprising a stable solution of cyromazine, or a pharmaceutically acceptable salt thereof, in a solvent system which may comprise water and one or more polyethylene glycols. A liquid concentrate is also described in which the cyromazine, or a pharmaceutically acceptable salt thereof, may be dissolved in a liquid PEG and is capable of being diluted with water before use. | 12-10-2009 |
20090312332 | COMPOUNDS FOR THE TREATMENT OF AURICULAR FIBRILLATION - Adenosine A | 12-17-2009 |
20090325966 | s-Triazine compounds, pharmaceutical compositions and method of using the same - Novel s-triazine compounds are disclosed that have a formula represented by the following: | 12-31-2009 |
20090325967 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS - A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, formula (1), or stereoisomers or pharmaceutically acceptable salts thereof, wherein A, U | 12-31-2009 |
20100029653 | PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS - The present application relates to novel azabicyclic compounds, processes for their preparation, their use alone or in combinations for the treatment and/or prevention of diseases, and their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders. | 02-04-2010 |
20100069391 | Novel sEH Inhibitors and Their Use - The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. | 03-18-2010 |
20100113456 | THERAPEUTIC AGENT FOR CORNEAL DISEASE - A therapeutic agent for a corneal disease comprising irsogladine or a salt thereof as an active ingredient. The purpose is to find a substance capable of effectively treating/ameliorating a corneal disease which has been increased in the number of cases thereof in recent years and to provide a therapeutic agent for a corneal disease comprising the substance as an active ingredient. | 05-06-2010 |
20100120771 | AURORA KINASE INHIBITORS FROM AN ENCODED SMALL MOLECULE LIBRARY | 05-13-2010 |
20100120772 | P38 KINASE INHIBITORS - Compounds of formula (I) and (II) are disclosed, as well as methods for their identification, their preparation, pharmaceutical compositions containing them, and their use in treating disease. The compounds inhibit the production of TNF-alpha and interleukins (IL) by the inhibition of p38 kinase. They are useful in the treatment of inflammation and arthritis. | 05-13-2010 |
20100120773 | METHOD OF TREATING DISORDERS MEDIATED BY THE FIBROBLAST GROWTH FACTOR RECEPTOR - The disclosure includes a method of treating a warm-blooded animal having a disorder mediated by the fibroblast growth factor receptor (FGFR), in particular 8p11 myelo-proliferative syndrome (EMS), pituitary tumors, retinoblastoma, synovial sarcoma, chronic obstructive pulmonary disease (COPD), seborrheic keratosis, obesity, diabetes and related disorders, autosomal dominant hypophosphatemic Rickets (ADHR), X-chromosome linked hypophosphatemic rickets (XLH), tumor-induced osteomalacia (TIO) and fibrous dysplasia of the bone (FD), as well as to a method of promoting localized neochondrogenesis, as well as a method of treating hepatocellular carcinoma, lung cancer, especially pulmonary adnocarcinoma, oral squameous cell carcinoma, or esophageal squameous cell carcinoma, or any combination of two or more such diseases. | 05-13-2010 |
20100168115 | USE OF TRIAZINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT HAVING A CICATRISING OR ANGIOGENIC EFFECT - The present patent application relates to the use of triazine derivatives as cicatrising or angiogenic agents, wherein the triazine is a molecule of formula (I). | 07-01-2010 |
20100190794 | Herbicidally Active Composition - The present invention relates to herbicidally active compositions comprising at least one piperazinedione compound of the formula I | 07-29-2010 |
20100210654 | NOVEL P2Y12 RECEPTOR ANTAGONISTS - The present invention relates to novel P2Y | 08-19-2010 |
20100210655 | NOVEL sEH INHIBITORS AND THEIR USE - The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: | 08-19-2010 |
20100210656 | NOVEL sEH INHIBITORS AND THEIR USE - The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: | 08-19-2010 |
20100222352 | Compounds and Methods for the Treatment of Viruses and Cancer - The present invention relates to compounds according to the formula I: Where R | 09-02-2010 |
20100249137 | Novel sEH Inhibitors and Their Use - The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to (Cis)-N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof, and N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof. | 09-30-2010 |
20100267729 | FUNGICIDAL HETEROCYCLIC AMINES - Disclosed are compounds of Formula 1, N-oxides, and salts thereof, | 10-21-2010 |
20110086857 | N-((1R,2S,5R)-5-(TERT-BUTYLAMINO)-2-((S)-3-(7-TERT-BUTYLPYRAZOLO[1,5-A][1,- 3,5]TRIAZIN-4-YLAMINO)-2-OXOPYRROLIDIN-1-YL)CYCLOHEXYL)ACETAMIDE, A DUAL MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESSES - The present invention provides a novel antagonist: N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide: | 04-14-2011 |
20110105508 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS - A series of heteroaryl-substituted quinoxaline and quinoline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 05-05-2011 |
20110124649 | INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS - Described herein are novel pyrimidine-pyridine compounds, methods of inhibiting methionine aminopeptidase and treating disorders (or symptoms thereof) associated with methionine aminopeptidase, wherein a compound of the invention is administered to a subject. | 05-26-2011 |
20110136811 | PROKINETICIN 1 RECEPTOR - The present invention relates to methods of monitoring the biological activity of the PK1 receptor. | 06-09-2011 |
20110144114 | SUBSTITUTED TRIAZINONE DERIVATIVES - Triazinone derivatives represented by formula (I) | 06-16-2011 |
20110152269 | PROCESS FOR TREATING ANIMAL HABITATS - This invention deals with a process for treating and sanitizing animal habitats. In addition to sanitizing the habitat the production of ammonia and odor from fecal matter and urine is inhibited or terminated. In the process an animal habitat is cleaned and subsequently treated with trichloromelamine (TCM). The TCM may be applied by spraying the habitat with a solution of TCM, by dusting the habitat with powdered TCM or by treating bedding/litter with TCM. This process produces healthier animals and as such the productivity of a given grow out is increased. The process of this invention is particularly suited to animal habitats which are used to raise batches of hogs, cattle, turkeys and chickens on a continuing basis. The process of this invention further reduces the bacteria count of the animal habitat. | 06-23-2011 |
20110195968 | THIAZOLES AS FUNGICIDES - Use of compounds of the formula (I), | 08-11-2011 |
20110207736 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH - Provided are compounds and methods for treating or preventing kinase-mediated disorders therewith. | 08-25-2011 |
20110230489 | s-TRIAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME - Novel s-triazine compounds are disclosed that have a formula represented by the following: | 09-22-2011 |
20110237594 | FUNGICIDE HERETOCYCLYL-TRIAZINYL-AMINO DERIVATIVES - The present invention relates to heterocyclyl-triazinyl-amino derivatives of formula (I) | 09-29-2011 |
20110275640 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound - The present invention relates to preventives or remedies for Alzheimer's disease, or to amyloid protein fibril-formation inhibitors, which include as an active ingredient a compound of general formula (I) below or a pharmacologically permitted salt thereof; and also to nitrogen-containing heteroaryl derivatives having specific substituents, or pharmacologically permitted salts thereof, which are valuable as preventives or remedies for Alzheimer's disease, or as amyloid protein fibril-formation inhibitors: | 11-10-2011 |
20110275641 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound - The present invention relates to preventives or remedies for Alzheimer's disease, or to amyloid protein fibril-formation inhibitors, which include as an active ingredient a compound of general formula (I) below or a pharmacologically permitted salt thereof; and also to nitrogen-containing heteroaryl derivatives having specific substituents, or pharmacologically permitted salts thereof, which are valuable as preventives or remedies for Alzheimer's disease, or as amyloid protein fibril-formation inhibitors: | 11-10-2011 |
20110319417 | METHODS AND COMPOSITIONS FOR TREATING ANXIETY - Methods of treating a TRPC5 mediated disorder in a subject by administering an effective amount of a TRPC5 antagonist, such as a compound disclosed herein, are described. | 12-29-2011 |
20110319418 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN - Disclosed are compounds, compositions and methods for treating pain, including inflammatory, visceral, and acute pain. Such compounds are represented by Formula (I) as follows: | 12-29-2011 |
20120071482 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES - This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia. | 03-22-2012 |
20120077815 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors - A series of amino-substituted fused pyridine and pyrazine derivatives, in particular amino-substituted quinoline and quinoxaline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 03-29-2012 |
20120083498 | Modulators of Viral Transcription, and Methods and Compositions Therewith - Processes to treat human immunodeficiency virus (HIV) infection are included. | 04-05-2012 |
20120088771 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP): A THERAPEUTIC TARGET FOR ARTERIAL CALCIFICATION - This invention relates generally to the field of mineralization, and specifically to the role of TNAP in regulating the levels of extracellular inorganic pyrophosphate. The invention provides methods for modulating the activity of TNAP activity; methods for screening for modulators of TNAP activity; modulators of TNAP activity; and methods for treating pathologic conditions known of suspected to be affected by modulation of TNAP activity. | 04-12-2012 |
20120088772 | NOVEL PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER - The present invention is to provide a therapeutic agent for attention deficit/hyperactivity disorder having a novel mechanism of action which is different from conventional psychostimulants. The present invention is useful for providing an excellent pharmaceutical composition for prevention and/or treatment of attention deficit/hyperactivity disorder, comprising a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, and is particularly useful for providing a pharmaceutical composition for prevention and/or treatment of inattention, impulsivity, and hyperactivity in attention deficit/hyperactivity disorder. | 04-12-2012 |
20120095005 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors - A series of substituted pyrazolo[1,5-α][1,3,5]triazine and pyrazolo[1,5-αj-pyrimidine derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I). | 04-19-2012 |
20120115872 | COMBINATION OF A SODIUM-PROTON EXCHANGER INHIBITOR AND OF A DIHYDRO-1,3,5-TRIAZINE AMINE DERIVATIVE - The invention relates to a combination of a sodium-proton exchanger inhibitor and of a dihydro-1,3,5-triazine amine derivative which is useful for the treatment and/or prevention of pathologies induced by ischaemia and/or reperfusion, especially cardiac and renal complications. | 05-10-2012 |
20120122873 | AMINO DERIVATIVES OF DIHYDRO-1,3,5-TRIAZINE USED IN THE TREATMENT OF ISCHEMIA AND/OR REPERFUSION RELATED DISEASES - The invention relates to amino derivatives of dihydro-1,3,5-triazine, used for the treatment and/or prevention of diseases induced by ischemia and/or reperfusion, notably cardiac and renal complications. | 05-17-2012 |
20120129862 | PROKINETICIN 1 RECEPTOR ANTAGONISTS - The present invention relates to certain novel compounds of Formula (I): | 05-24-2012 |
20120135994 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA - Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo. | 05-31-2012 |
20120149708 | MODULATORS OF VIRAL TRANSCRIPTION, AND METHODS AND COMPOSITIONS THEREWITH - The present invention is directed to a process for inhibiting the replication of human immunodeficiency virus-1 (HIV-1), by contacting a cell with at least one compound according to Formula I. | 06-14-2012 |
20120165334 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors - The present invention provides compounds that are kinase inhibitors, specifically PIK kinase inhibitors, more specifically, mTOR inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of kinases, specifically PIK kinase inhibitors, more specifically, mTOR such as cancer. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. | 06-28-2012 |
20120172364 | RATE-CONTROLLED PARTICLES - Rate-controlled particles, comprising compounds of the formula | 07-05-2012 |
20120178758 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS - The invention provides Styryl-Triazine derivatives, and further provides methods of using these compounds to modulate protein kinases and to treat protein kinase mediated diseases. | 07-12-2012 |
20120184557 | PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - A compound of formula (I), or a pharmaceutically acceptable salt thereof, where R | 07-19-2012 |
20120190683 | INSECTICIDAL SUBSTITUTED AZINYL DERIVATIVES - N-Azinyl-N′-aryl ureas and thioureas derivatives are effective at controlling insects. | 07-26-2012 |
20120190684 | INSECTICIDAL SUBSTITUTED AZINYL DERIVATIVES - N-Azinyl-N′-aryl ureas and thioureas derivatives are effective at controlling insects. | 07-26-2012 |
20120202818 | UREIDOPHENYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS - The present invention provides Uredophenyl substituted triazine derivatives and provides methods of using these compounds to modulate protein kinases and methods of using these compounds to treat protein kinase mediated diseases and conditions. | 08-09-2012 |
20120264758 | ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO - Disclosed are antimicrobial compositions for treating poultry and meat to substantially eliminate bacteria and microorganism harmful to human. The compositions include various combinations of an aliphatic heteroaryl salt, an aliphatic benzylalkyl ammonium salt, a dialiphatic dialkyl ammonium salt, a tetraalkyl ammonium salt and/or trichloromelamine. | 10-18-2012 |
20120264759 | BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS - The invention provides triazine compounds and methods of their use to modulate protein kinases and to treat diseases mediated by said protein kinases. | 10-18-2012 |
20120277235 | Compositions For Topical Application Having Androgenic Actions - A composition comprising at least one physiologically tolerated film forming agent, at least one physiologically tolerated solvent, at least one plasticizer and a compound of the formula I | 11-01-2012 |
20120277236 | METHOD FOR INHIBITING MMP-9 DIMERIZATION - A method of inhibiting matrix metalloproteinase 9 (MMP-9) dimerization without substantially inhibiting the catalytic activity of MMP-9, comprising contacting the MMP-9 with a small molecule compound of the structure | 11-01-2012 |
20120283263 | TRIAZINE-ARYL-BIS-INDOLES AND PROCESS FOR PREPARATION THEREOF - A novel heterocyclic compound belonging to ‘triazine-aryl-bis-indoles’, useful for the treatment of asthma. The pathway by which this compound inhibits asthma is also demonstrated. The present invention also provides a process for the preparation of above compounds and their derivatives are presented. | 11-08-2012 |
20120295911 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases - The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention. | 11-22-2012 |
20130059855 | CRYSTAL OF DI(ARYLAMINO)ARYL COMPOUND - Provided are crystals of compound A which have properties suitable for industrial production. | 03-07-2013 |
20130109693 | DERIVATIVES OF PYRIDO [3,2-D] PYRIMIDINE, METHODS FOR PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | 05-02-2013 |
20130109694 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY AGAINST CLOSTRIDIUM | 05-02-2013 |
20130131065 | TREATMENT OF TYPE 2 DIABETES - The present invention relates to triazine derivatives of Formula I for their use in the treatment of Type 2 diabetes, and to compositions comprising said triazine derivatives. | 05-23-2013 |
20130131066 | TREATMENT OF TYPE 1 DIABETES - The present invention relates to triazine derivatives of formula (I) for their use in the treatment of type 1 diabetes mellitus, and to compositions comprising said triazine derivatives. | 05-23-2013 |
20130158038 | NOVEL COMPOUNDS - This invention relates to compounds of formula I | 06-20-2013 |
20130158039 | N-((1R,2S,5R)-5-(TERT-BUTYLAMINO)-2-((S)-3-(7-TERT-BUTYLPYRAZOLO[1,5-A][1,- 3,5]TRIAZIN-4-YLAMINO)-2-OXOPYRROLIDIN-1-YL)CYCLOHEXYL)ACETAMIDE, A DUAL MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESSES - The present invention provides a novel antagonist: N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide: | 06-20-2013 |
20130178475 | sGC STIMULATORS - Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed. | 07-11-2013 |
20130261124 | THERAPEUTIC METHODS AND AGENTS FOR TREATING MYOTONIC DYSTROPHY - The invention provides compounds, compositions and methods for treating myotonic dystrophy. The compounds can selectively bind to CUG repeats in RNA, or to CTG repeats in DNA, and inhibit replication of the nucleic acids. | 10-03-2013 |
20130310388 | Modulators of TNF-Alpha Signaling - The present invention provides compounds which are modulators of TNF-α signaling and methods of use thereof for treating a patient having a TNF-α mediated condition. The compounds can be represented by the following structural formulas: | 11-21-2013 |
20140011810 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith - Provided are compounds and methods for treating or preventing kinase-mediated disorders therewith. | 01-09-2014 |
20140038968 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS - The present invention relates to certain novel compounds of Formula (I): | 02-06-2014 |
20140045852 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES - The present invention relates to substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). | 02-13-2014 |
20140088109 | N-((1R,2S,5R)-5-(TERT-BUTYLAMINO)-2-((S)-3-(7-TERT-BUTYLPYRAZOLO[1,5-A][1,- 3,5]TRIAZIN-4-YLAMINO)-2-OXOPYRROLIDIN-1-YL)CYCLOHEXYL)ACETAMIDE, A DUAL MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESSES - The present invention provides a novel antagonist: N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin -1-yl)cyclohexyl)acetamide: | 03-27-2014 |
20140100230 | METHODS AND COMPOSITIONS FOR TREATING ANXIETY - Methods of treating a TRPC5 mediated disorder in a subject by administering an effective amount of a TRPC5 antagonist, such as a compound disclosed herein, are described. | 04-10-2014 |
20140113900 | SUBSTITUTED IMIDAZOPYRIDINES AND THE USE THEREOF - The present application relates to novel substituted imidazopyridazines, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases and to their use for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders. | 04-24-2014 |
20140135335 | SPIRO BICYCLIC OXALAMIDE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C - Compounds of Formula I, including pharmaceutically acceptable salts, as well as compositions containing these compounds, have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: | 05-15-2014 |
20140194429 | COMPOSITIONS FOR TREATMENT OF CANCER - Compounds that are specifically toxic to cancer stem cells are disclosed. | 07-10-2014 |
20140288080 | THERAPEUTIC METHODS AND AGENTS FOR TREATING MYOTONIC DYSTROPHY - The invention provides compounds, compositions and methods for treating myotonic dystrophy. The compounds can selectively bind to CUG repeats in RNA, or to CTG repeats in DNA, and inhibit replication of the nucleic acids. | 09-25-2014 |
20140296242 | COMPOUNDS FOR TREATING CANCER, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS - Some embodiments of this invention include methods for treating disease and methods for administering a compound of the invention. In some aspects of the invention, diseases can be treated by administration of compositions comprising a compound of the invention. Pharmaceutical compositions of some embodiments of the present invention comprise a compound of the invention. | 10-02-2014 |
20140315906 | 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES CONTAINING A SULFOXIMINE GROUP - The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia). | 10-23-2014 |
20140323488 | DISUBSTITUTED TRIAZINE DIMERS FOR TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES - The present invention relates to novel compounds (I) containing two disubstituted triazine rings covalently linked by an organic linker, thereby creating dimers. These compounds show activity against the causative infective agents of infectious diseases such as African trypanosomiasis, Chagas disease, Leishmaniasis, Malaria and HIV. The invention further relates to the prevention and/or treatment of these diseases. | 10-30-2014 |
20140329822 | N-PIPERIDIN-4-YL DERIVATIVES - The invention relates to a N-piperidin-4-yl derivative having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same and to the use of said N-piperidin-4-yl derivatives for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, or for the treatment of uterine fibroids or other menstrual-related disorders. | 11-06-2014 |
20140371224 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES - The present invention includes compounds, and compositions comprising the same, that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention. | 12-18-2014 |
20150031698 | s-TRIAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME - Novel s-triazine compounds are disclosed that have a formula represented by the following: | 01-29-2015 |
20150057285 | BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS - The invention provides triazine compounds and methods of their use to modulate protein kinases and to treat diseases mediated by said protein kinases. | 02-26-2015 |
20150094310 | CRHR1 ANTAGONISTS FOR USE IN THE TREATMENT OF PATIENTS HAVING CRH OVERACTIVITY - The present invention relates to a corticotropin releasing hormone receptor type 1 (CRHR1) antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in a novel group of patients, i.e. patients having corticotropin releasing hormone (CRH) overactivity. | 04-02-2015 |
20150126512 | Modulators Of TNF-Alpha Signaling - The present invention provides compounds which are modulators of TNF-α signaling and methods of use thereof for treating a patient having a TNF-α mediated condition. The compounds can be represented by the following structural formulas: | 05-07-2015 |
20150291597 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME - The present invention includes compositions that are useful in the prevention and/or treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of preventing and/or treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of the invention. | 10-15-2015 |
20150320045 | SYNERGISTIC COMBINATION OF A LENACIL COMPOUND AND TERBUTRYN FOR DRY FILM PROTECTION - A synergistic antimicrobial composition containing lenacil and terbutryn is provided. Also provided is a method of inhibiting the growth of or controlling the growth of microorganisms in a building material by adding such a synergistic antimicrobial composition. Also provided is a coating composition containing such a synergistic antimicrobial composition, and a dry film made from such a coating composition. | 11-12-2015 |
20150322020 | SQUARIC DERIVATIVES FOR THE TREATMENT OF HEPATITIS C - Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 11-12-2015 |
20150366191 | ANTIMICROBIAL METHOD BY BLOCKING MANNITOL METABOLISM AND ANTIMICROBIAL COMPOSITION CONTAINING MANNITOL METABOLIC INHIBITOR - The present invention relates to an antimicrobial method of killing bacteria having a mannitol metabolic pathway by inhibition of a mannitol metabolism, a method of screening a mannitol metabolic inhibitor, and an antimicrobial composition and cosmetic material containing a mannitol metabolic inhibitor. More particularly, the present invention relates to an antimicrobial method targeted at mannitol dehydrogenase such as mannitol-1-phosphate-5-dehydrogenase (M1PDH), a method of screening an inhibitor, and a composition. Therefore, the antimicrobial method, antimicrobial composition, and cosmetic material which solve a problem of antibiotic resistance and have an excellent antimicrobial effect may be provided. | 12-24-2015 |
20160046610 | 3-HETEROARYL SUBSTITUTED INDAZOLES - Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals. | 02-18-2016 |
20160047001 | Sept4/ARTS AS A TUMOR SUPPRESSOR IN THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF HEPATIC DISORDERS - The invention relates to methods for the diagnosis and prognosis of hepatic disorder and associated pathologies as well as of a solid proliferative disorder in a mammalian subject. More specifically, the methods of the invention are based on determining the expression, methylation of ARTS as well as histone trimethylation. The invention further provides therapeutic methods for treating said disorders. | 02-18-2016 |
20160052914 | COMPOUNDS AND METHODS FOR MYOTONIC DYSTROPHY THERAPY - The invention provides rationally designed multi-targeting therapeutic agents for myotonic dystrophy type 1 (DM1), an incurable neuromuscular disease that originates in an abnormal expansion of CTG repeats (CTG | 02-25-2016 |
20160089374 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE - Provided are compounds useful for treating cancer and methods of treating cancer, for example an advanced solid tumor, such as a glioma, or angioimmunoblastic T-cell lymphoma (AITL). | 03-31-2016 |
20160089375 | TOPICAL OCULAR ANALGESIC AGENTS - The topical ophthalmic use of certain 2,4-diamino-substituted 1,3-triazines for preventing or alleviating ocular pain in patients is disclosed. Topical ocular pharmaceutical composition are also disclosed. | 03-31-2016 |
20160113933 | TREATMENT OF OBESITY AND PULMONARY ARTERIAL HYPERTENSION - Disclosed are methods and compositions for treating pulmonary arterial hypertension and/or obesity using inhibitors of prostaglandin transporter (PGT) activity. | 04-28-2016 |
20160115151 | AMINOTRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention provides novel compounds having a P2X | 04-28-2016 |
20160145243 | Novel Anti-Cancer Agents - The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. | 05-26-2016 |
20160145244 | CERTAIN PROTEIN KINASE INHIBITORS - Provided are certain ALK inhibitors, pharmaceutical compositions thereof, and methods of use therefor. | 05-26-2016 |
20160153043 | METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS | 06-02-2016 |
20160158241 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER - Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer. | 06-09-2016 |
20160159771 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE - Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein. | 06-09-2016 |
20160194305 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | 07-07-2016 |
20180022715 | N2-(3,4-DIMETHYLPHENYL)-6-((4-(P-TOLYL)PIPERAZIN-1-YL)METHYL)-1,3,5-TRIAZI- NE-2,4-DIAMINE | 01-25-2018 |
20220135535 | HETEROARYL COMPOUNDS AND THEIR USE - The application is directed to compounds of formula (I): and their salts and solvates, wherein R | 05-05-2022 |